GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lumos Pharma Inc (FRA:4NX1) » Definitions » Shiller PE Ratio

Lumos Pharma (FRA:4NX1) Shiller PE Ratio : (As of May. 21, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Lumos Pharma Shiller PE Ratio?

Note: If the price history is too short, we do not calculate current Shiller PE for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Lumos Pharma Shiller PE Ratio Historical Data

The historical data trend for Lumos Pharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Pharma Shiller PE Ratio Chart

Lumos Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Lumos Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lumos Pharma's Shiller PE Ratio

For the Biotechnology subindustry, Lumos Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lumos Pharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lumos Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Lumos Pharma's Shiller PE Ratio falls into.



Lumos Pharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Lumos Pharma's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Lumos Pharma's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0/131.7762*131.7762
=0.000

Current CPI (Mar. 2024) = 131.7762.

Lumos Pharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -19.673 100.560 -25.780
201409 -12.571 100.428 -16.495
201412 266.049 99.070 353.881
201503 26.195 99.621 34.650
201506 -35.364 100.684 -46.285
201509 -39.694 100.392 -52.103
201512 -55.769 99.792 -73.643
201603 -59.645 100.470 -78.230
201606 -80.741 101.688 -104.631
201609 -38.972 101.861 -50.418
201612 -35.323 101.863 -45.696
201703 -54.529 102.862 -69.857
201706 -41.091 103.349 -52.393
201709 -46.892 104.136 -59.338
201712 -25.325 104.011 -32.085
201803 -32.189 105.290 -40.286
201806 -32.588 106.317 -40.392
201809 -13.883 106.507 -17.177
201812 -19.936 105.998 -24.784
201903 -1.885 107.251 -2.316
201906 -2.186 108.070 -2.666
201909 -2.324 108.329 -2.827
201912 -1.782 108.420 -2.166
202003 -0.127 108.902 -0.154
202006 -0.577 108.767 -0.699
202009 0.178 109.815 0.214
202012 -0.255 109.897 -0.306
202103 -0.874 111.754 -1.031
202106 -0.822 114.631 -0.945
202109 0.000 115.734 0.000
202112 0.000 117.630 0.000
202203 0.000 121.301 0.000
202206 0.000 125.017 0.000
202209 0.000 125.227 0.000
202212 0.000 125.222 0.000
202303 0.000 127.348 0.000
202306 0.000 128.729 0.000
202309 0.000 129.860 0.000
202312 0.000 129.419 0.000
202403 0.000 131.776 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Lumos Pharma  (FRA:4NX1) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Lumos Pharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Lumos Pharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Lumos Pharma (FRA:4NX1) Business Description

Traded in Other Exchanges
Address
4200 Marathon Boulevard, Suite 200, Austin, TX, USA, 78756
Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates primarily in the United States.

Lumos Pharma (FRA:4NX1) Headlines

No Headlines